Blog

Pfizer Limited released its Q1 results with notable financial changes:

• Net Profit Surge: Pfizer’s net profit for the quarter ending June 2023 witnessed an impressive 187% YoY increase, reaching ₹93.5 crore. However, sequentially, the net profit plummeted by 27% compared to the previous quarter’s figure of ₹129.6 crore during the quarter ending March 2023.
• Revenue from Operations: The Company’s revenue from operations experienced a 10% YoY decline, amounting to ₹531.3 crore during the quarter, down from ₹593 crore in the same period of the previous fiscal. Sequentially, the revenue from operations was reported at ₹572.6 crore in Q4FY23.
• Earnings Per Share (EPS): Pfizer’s Earning Per Share (EPS) demonstrated a significant jump from ₹7.11 during Q1FY23 to ₹20.44 during the quarter under review. Sequentially, the EPS (both basic and diluted) stood at ₹28.34 for the quarter ending March 2023.
• Dividend Declaration: In the previous quarter ending March 2023, Pfizer declared a final dividend of ₹35 per share and a special dividend of ₹5 per share for FY23.
• Recall of Products: During the April-June quarter, Pfizer initiated a voluntary recall of three products—Magnex, Magnamycin, and Zosyn—manufactured by Astral SteriTech Private Limited due to ongoing investigations by Astral. The products recorded a sale of ₹139.25 crore during the year ending March 31, 2023.
• Share Performance: Pfizer Limited’s shares experienced a 1.6% decrease, closing at ₹3,975 apiece on Friday.

Pfizer’s Q1 results depict significant fluctuations, including a remarkable YoY net profit increase but a notable decline in revenue from operations. The voluntary recall of products adds an element of transparency and responsibility, and the share performance reflects the market’s response to the disclosed results.